Completed PHASE1 INTERVENTIONAL 1-arm NCT00104910

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer

Sponsor: Gynecologic Oncology Group

Conditions Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma Stage IB Cervical Cancer Stage IIA Cervical Cancer Stage IIB Cervical Cancer Stage III Cervical Cancer Stage IVA Cervical Cancer

Interventions 3-Dimensional Conformal Radiation Therapy Cetuximab Cisplatin Internal Radiation Therapy

Updated 8 times since 2017 Last updated: Dec 29, 2014 Started: Jan 31, 2005 Primary completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cervical Adenocarcinoma and Cervical Adenosquamous Carcinoma and is currently completed. Gynecologic Oncology Group leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Feb 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gynecologic Oncology Group
National Cancer Institute (NCI)

Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augusta, United States , Baltimore, United States , Camden, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Houston, United States , Indianapolis, United States , Iowa City, United States and 3 more locations